help your dog live longer.
Buy Rapamycin now.
Rapamycin for Dogs with Cancer
Rapamycin is commonly used to fight cancer in humans, and there are a number of ongoing clinical trials studying the use of rapamycin for dogs with cancer.
Rapamycin targets mTOR, an important regulator of cell division and tumor blood supply. By inhibiting mTOR, rapamycin can in theory reduce tumor growth, tumor nourishment, and tumor spread via new blood vessels. Learn more about how rapamycin works here.
Here’s a summary of using rapamycin for dogs with cancer….
Rapamycin for Dogs with Lymphoma
Study 1: the pAKT/mTOR pathway is present only in malignant, but not normal, lymphoblasts. A novel pAKT/mTOR inhibitor produced dose-dependent inhibition of malignant cell proliferation
Study 2: Low dose rapamycin inhibited lymphoma cell proliferation, while high dose rapamycin actively killed lymphoma cells.
Study 3: Aberrant mTOR regulation plays a role in many blood cancers, and thus mTOR inhibitors like rapamycin should be routinely considered in their management.
Rapamycin for Dogs with Hemangiosarcoma
Study 1: Low dose rapamycin inhibited HSA cell proliferation, while high dose rapamycin actively killed HSA cells.
Study 2: Inhibitors of the pI3K/AKT/mTOR pathways reduce the proliferation of canine HSA cells.
Study 3: In vitro effects of rapamycin on canine HSA cells
Clinical Trial on rapamycin and canine HSA
Rapamycin for Dogs with Osteosarcoma
Rapamycin for Dogs with Melanoma
Study 1: mTOR is present and active in multiplying melanoma cells. Rapamycin, through its mTOR inhibition, will inhibit melanoma cell proliferation and tumor growth.
Study 2: mTOR is present and active in melanoma skin tumors, and thus rapamycin and other mTOR inhibitors may be a logical intervention.
Study 3: mTOR inhibitors are synergistic with carboplatin in the treatment of canine melanoma
Rapamycin for Dogs with Mammary Cancer
Study 1: Low dose rapamycin inhibited mammary cancer cell proliferation, while high dose rapamycin actively killed mammary cancer cells.
Study 2: activated mTOR was not found in normal dog mammary tissue, but was present in 78% of canine mammary tumors.
Study 3: Overview of mTOR inhibition for breast cancer